Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Hypoxia-Inducible Factors Activate Breast Cancer Metastatic Genes

By BiotechDaily International staff writers
Posted on 06 Jan 2014
Image: A breast cancer cell in normal oxygen conditions (Photo courtesy of Dr. Daniele Gilkes, Johns Hopkins University).
Image: A breast cancer cell in normal oxygen conditions (Photo courtesy of Dr. Daniele Gilkes, Johns Hopkins University).
Image: In low oxygen conditions, breast cancer cells form structures that facilitate movement, such as filaments that allow the cell to contract (green) and cellular \"hands\" that grab surfaces to pull the cell along (red) (Photo courtesy of Dr. Daniele Gilkes, Johns Hopkins University).
Image: In low oxygen conditions, breast cancer cells form structures that facilitate movement, such as filaments that allow the cell to contract (green) and cellular \"hands\" that grab surfaces to pull the cell along (red) (Photo courtesy of Dr. Daniele Gilkes, Johns Hopkins University).
Factors related to hypoxia, the condition of low oxygen content that characterizes the microenvironment surrounding breast tumors, have been linked to the activation of genes that encode proteins that transform benign breast cancer cells into mobile and invasive metastatic cells.

Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment, specifically, to decreases in oxygen, or hypoxia. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM (extracellular matrix) as well as genes that control motility and adhesion of tumor cells. HIF activity is upregulated by mutated RAS, a member of the KRAS family of oncogenes, and BRAF (v-raf murine sarcoma viral oncogene homolog B1) as well as loss-of-function mutations of the PTEN gene. PTEN (phosphatase and tensin homolog), which is missing in 60%–70% of metastatic cancers in humans, is the name of a phospholipid phosphatase protein, and gene that encodes it. The PTEN gene acts as a tumor suppressor gene thanks to the role of its protein product in regulation of the cycle of cell division, preventing cells from growing and dividing too rapidly.

Investigators at Johns Hopkins University (Baltimore, MD, USA) reported in the December 9, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that HIFs triggered metastasis by increasing the activity of the proteins RhoA and ROCK1.

RhoA (Ras homolog gene family, member A) is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. This protein is essential for the signaling function of the Rho GTPase complex. Previous studies have shown that in breast cancer increased RhoA activity stimulated cancer cell invasiveness and spreading, while RhoA deficiency suppressed cancer growth and progression. Rho kinase 1 (ROCK1) is a kinase that regulates myosin light-chain activity, leading to actin-myosin contraction, which is the basis for cell movement.

The investiagors found that the RhoA-bound ROCK1 complex phosphorylated myosin light chain (MLC), which was required for actin-myosin contractility. RhoA also activated focal adhesion kinase (FAK) signaling. Increased activity of these two proteins led to cell and matrix contraction, focal adhesion formation, and motility through the phosphorylation of MLC and FAK.

“As tumor cells multiply, the interior of the tumor begins to run out of oxygen because it is not being fed by blood vessels,” said senior author Dr. Gregg Semenza, professor of medicine at Johns Hopkins University. “The lack of oxygen activates the hypoxia-inducible factors, which are master control proteins that switch on many genes that help cells adapt to the scarcity of oxygen."

“High levels of RhoA and ROCK1 were known to worsen outcomes for breast cancer patients by endowing cancer cells with the ability to move, but the trigger for their production was a mystery,” said Dr. Semenza. “We now know that the production of these proteins increases dramatically when breast cancer cells are exposed to low oxygen conditions.”

Related Links:

Johns Hopkins University



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.